Casdin Capital, LLC
NEW YORK, NY · Quarter end: Sep 30, 2026 · Filed with SEC: Nov 16, 2026 · Open the SEC source ↗
Portfolio Return (1Y)——
Portfolio Value (AUM)Total value of the fund's US stock portfolio reported to the SEC.$2.30B2026 Q3
Positions48
Top-10 ConcentrationPercent of the portfolio in the 10 largest holdings. High means the fund is concentrated in few stocks.76.1%
What Changed This Quarter?
Top Holdings
RVMD
Revolution Medicines
23.0%
RLAY
Relay Therapeutics
12.6%
WGS
GeneDx
11.7%
BLFS
Biolife Solutions
7.6%
ILMN
Illumina
6.3%
GRAL
Grail
4.2%
TXG
10x Genomics
4.1%
LAB
Standard Biotools
2.9%
Read the 2026-Q2 quarterly report · 13F Filing Calendar
13F data shows quarter-end positions, is delayed by up to 45 days and covers only long positions in US-listed securities; short positions, most derivatives and non-US assets are not reported.